Could istaroxime be a lifeline for shock patients?
NCT ID NCT07583446
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests the drug istaroxime in 600 adults with mild to moderate cardiogenic shock caused by acute heart failure. Participants receive a 48-hour IV infusion of istaroxime or a placebo, plus standard care. Researchers measure changes in blood pressure, breathing, and overall outcomes like survival and quality of life over 90 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- istaroxime
- What this could lead to
- If it works, istaroxime could become a new treatment to stabilize blood pressure and reduce complications in people with cardiogenic shock.
- What could go wrong
- This is an early-to-mid stage trial with 600 participants. The drug may not prove more effective than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOGENIC SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a temporary heart pump save more lives in cardiogenic shock?
- Could starting dialysis sooner save more hearts?
- A tiny probe into the heart's hidden reserve could forecast who needs a transplant
- Can a tiny heart pump Fine-Tune support for failing hearts?
- Could a key hormone be missing in septic shock?
- Could a simple filter tame the deadly inflammation of heart shock?